TY - JOUR
TI - Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenström macroglobulinemia: Final analysis of a phase 2 study
AU - Kastritis, E.
AU - Gavriatopoulou, M.
AU - Kyrtsonis, M.-C.
AU - Roussou, M.
AU - Hadjiharissi, E.
AU - Symeonidis, A.
AU - Repoussis, P.
AU - Michalis, E.
AU - Delimpasi, S.
AU - Tsatalas, K.
AU - Tsirigotis, P.
AU - Vassou, A.
AU - Vervessou, E.
AU - Katodritou, E.
AU - Gika, D.
AU - Terpos, E.
AU - Dimopoulos, M.A.
JO - Blood advances
PY - 2015
VL - 126
TODO - 11
SP - 1392-1394
PB - American Society of Hematology
SN - null
TODO - 10.1182/blood-2015-05-647420
TODO - cyclophosphamide;  dexamethasone;  rituximab;  antineoplastic agent;  cyclophosphamide;  dexamethasone;  rituximab, adult;  aged;  cancer patient;  disease course;  human;  intention to treat analysis;  Letter;  multiple cycle treatment;  phase 2 clinical trial (topic);  priority journal;  progression free survival;  remission;  treatment outcome;  treatment response;  Waldenstroem macroglobulinemia;  clinical trial;  controlled study;  disease free survival;  middle aged;  multicenter study;  phase 2 clinical trial;  randomized controlled trial;  very elderly;  Waldenstrom Macroglobulinemia, Aged;  Aged, 80 and over;  Antineoplastic Combined Chemotherapy Protocols;  Cyclophosphamide;  Dexamethasone;  Disease Progression;  Disease-Free Survival;  Humans;  Middle Aged;  Rituximab;  Treatment Outcome;  Waldenstrom Macroglobulinemia
TODO - null
ER -